On May 8, 2024, the U.S. District Judge Gene E.K. Pratter entered Case Management Order No. 6 establishing the expanded Leadership Structure in the “Ozempic lawsuits” [IN RE: GLUGAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) PRODUCTS LIABILITY LITIGATION (MDL 3094)].

Levin Papantonio Rafferty (LPR) Attorney Cameron Stephenson was appointed to the Plaintiffs’ Executive Committee in this MDL. In December 2023, Reuters interviewed Stephenson about the Ozempic lawsuits for its article exposing the growing litigation stemming from the dangers of these drugs, “As Ozempic cases mount, consumer lawyers push to consolidate lawsuits.”

About the Ozempic Lawsuits (GLP-1RA Lawsuits)

The Judicial Panel on Multidistrict Litigation (JPML) created multidistrict litigation MDL No. 3094 in February 2024. At that time, a Transfer Order was entered, centralizing lawsuits alleging that manufacturers of GLP-1 RA weight-loss drugs like Ozempic, Wegovy, and Rybelsus failed to adequately warn patients and doctors of the risk of dangerous gastrointestinal side effects.

Fifty-five pending actions and future tag-along cases were transferred to the Eastern District of Pennsylvania for the purpose of consolidating pretrial hearings. The MDL was assigned to the Honorable Gene E. K. Pratter.

LPR law firm is investigating cases wherein individuals received Ozempic, Rybelsus, or Wegovy brand GLP-1 RA treatments (in pills or via injections) and:

• Are 75 years of age or younger; and
• Received a diagnosis of gastroparesis, stomach paralysis or gastric obstruction while taking these drugs or within 30 days of stopping use; and
• Required an emergency room visit or hospital admission